Ingestible Camera Visualizes Small Intestine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

ROCKVILLE, Maryland-The FDA has approved a tiny ingestible video camera-the Given Diagnostic Imaging System (Given Imaging Ltd)-for use with other endoscopic and radiologic GI tract evaluations, to detect polyps, cancer, or causes of bleeding and anemia in the small intestine.

ROCKVILLE, Maryland—The FDA has approved a tiny ingestible video camera—the Given Diagnostic Imaging System (Given Imaging Ltd)—for use with other endoscopic and radiologic GI tract evaluations, to detect polyps, cancer, or causes of bleeding and anemia in the small intestine.

The system includes a single-use, 11 × 30-mm capsule, known as the M2A, which contains a color video-imaging unit, light source, telemetry transmitter, and battery.

The patient swallows the capsule, which passes through the GI tract and is excreted naturally. A window at one end of the capsule allows the camera to take images of the intestine lining (2 pictures every second) for about 8 hours, long enough to view the entire small intestine but not the whole colon.

Images are sent to a data recorder worn around the patient’s waist and later transferred for viewing to a workstation equipped with the company’s application software.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content